Kala Pharmaceuticals

Kala Pharmaceuticals is developing innovative medicines that have the unprecedented ability to rapidly and effectively penetrate mucosal barriers resulting in superior therapeutic efficacy and transformative treatment outcomes for patients.
Using its proprietary platform, Kala engineers Mucosal Penetrating Products (MPPs) that uniformly coat and rapidly permeate the mucosal surface to achieve improved distribution and prolonged retention, leading to sustained local concentration of drug. The result is a strong and durable therapeutic effect designed to enhance efficacy, often at a fraction of a standard therapeutic dose. The technology platform also enables drugs to reach sites of action after topical administration that are currently only accessed through more invasive techniques such as injections or implants.

Kala is advancing a diversified pipeline of transformative therapies for severe ophthalmic diseases for both front and back of eye. Two of its most advanced programs in development focus on topical treatment of ocular inflammation and wet AMD.

Beyond eye disease, Kala's proprietary MPPs offer the potential to treat a broad array of serious diseases that involve mucosal tissues such as in the, lungs, gastrointestinal tract, and female reproductive system, in new and more effective ways. Kala is pursuing collaborations with partners in these disease areas.